[1] JD MITCHELL AP D JJ Maguire. Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin S[J]. British Journal of Pharmacology, 2009, 158 1: 87-103. DOI:
10.1111/j.1476-5381.2009.00252.x[2] P G SZEKERES. Neuromedin U is a potent agonist at the orphan G protein-coupled receptor FM3.[J]. The Journal of Biological Chemistry, 2000, 275 27: 20247-20250. DOI:
10.1074/jbc.c000244200[3] M HOSOYA. Identification and functional characterization of a novel subtype of neuromedin U receptor.[J]. The Journal of Biological Chemistry, 2000, 275 38: 29528-29532. DOI:
10.1074/jbc.m004261200[4] PAUL J BRIGHTON. Paradoxical behavior of neuromedin U in isolated smooth muscle cells and intact tissue.[J]. Journal of Pharmacology and Experimental Therapeutics, 2008, 325 1: 154-164. DOI:
10.1124/jpet.107.132803[5] ANDREA PEIER. The antiobesity effects of centrally administered neuromedin U and neuromedin S are mediated predominantly by the neuromedin U receptor 2 (NMUR2).[J]. Endocrinology, 2009, 150 7: 3101-3109. DOI:
10.1210/en.2008-1772[6] X.H YU . Pro-nociceptive effects of neuromedin u in rat[J]. Neuroscience, 2003, 120 2: Pages 467-474. DOI:
10.1016/s0306-4522(03)00300-2